# Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

> **NCT00143481** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 400 (—)

## Conditions studied

- Urinary Incontinence

## Interventions

- **DRUG:** Tolterodine ER 4mg QD

## Key facts

- **NCT ID:** NCT00143481
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143481, "Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00143481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*